Skip to content
Medicines & Healthcare products Regulatory Agency
The National Institute for Biological Standards and Control

Confidence in biological medicines

  • Stay connected
  • Shopping Basket
  • Pay Now
  • Login / Register
  • Home
  • Products
  • Standardisation
  • Control testing
  • Science and research
  • Expert services
  • About us
  • QE2
  • Latest news
  • Worldwide impact of NIBSC
  • Mission and values
  • Careers
  • Quality and governance
  • Staff profiles
  • Contact us
  • Collaborations
  • Suppliers
  • Scientific Advisory Committee
  • Our use of animals
  • Privacy notice
  • Home  /  
  • About us  /  
  • Staff profiles  /  
  • Dr Nicola Rose

Dr Nicola Rose

Dr Nicola Rose joined NIBSC in 2001. She is a principal scientist in the live viral vaccines section of the Division of Virology and heads a group of pre- and post-doctoral scientists.

She has over 20 years’ experience in primate RNA viruses, models of infection and vaccination and host genetics gained primarily through working in the University of Cambridge, Department of Medicine (UK) and the former Division of Retrovirology at NIBSC, supported by a PhD in molecular genetics from the University of Leicester.

She is involved in the quality assessment of vaccines used in routine childhood vaccination programmes and those for emergency use. Her group is collaborating with the Chinese National Institutes for Food and Drug Control (NIFDC) to generate international standards for the assessment of Japanese encephalitis virus vaccine and immune responses.

Her research interests lie in 2 main areas. The assessment of viral vaccines and protective responses is currently focused on rotavirus and the group has current active collaborations with the Universities of Liverpool (PhD student) and Nottingham, and NIFDC. The group also has an interest in models of chronic viral disease, which has been supported by EU funding and Institute PhD studentships. She has over 35 refereed publications and has received a range of research funding including from the EU and the Medical Research Council (MRC).

Nicola supervises PhD students and coordinates the post-graduate programme at the Institute.

She is the Biological Safety Officer for NIBSC.

Current position

Acting Head of Viral Vaccines, Division of Virology

Areas of interest

Live viral vaccines
Primate RNA viruses
Models of chronic viral disease
Host genetic susceptibility

Qualifications

1993: PhD, University of Leicester
1990: BSc, Anglia Higher Education College

Recent publications (PDF, 103KB)

Representation on external committees

  • Committee on Human Medicines, Vaccine Stockpile Group
  • Public Health England: Biological Agents Steering Group
  • Public Health England: High Containment Biological Agent Leadership Group
  • Public Health England: Post-Graduate Training sub-committee
  • Public Health England: NHP Steering Group

External collaborators and funding bodies

FP7 Consortium
EUPRIM-Net
NIFDC 
Imperial College London
University of Liverpool
University of Nottingham

Funding secured over the past 10 year

  • Primary Applicant, Three NIBSC PhD Studentships. “The impact of vaccination against rotavirus on circulating wild type and vaccine strains in the UK”, 2015-2018; “Definition of immune responses in a model for HCV infection to develop and evaluate novel immunotherapeutic approaches”, 2011-2014; “Definition of vaccine responses in a model for hepatitis C virus”, 2007-2010
  • Co-applicant, NIBSC PhD Studentship. 3 years. £96k “Development of antibodies and characterisation of immune responses in a model for hepatitis C virus”, 2013-2016
  • Co-applicant, MRC Strategic Award. (2009-2010):  “Restoration of pathways implicated in T cell exhaustion following HCV infection”.
  • Primary applicant, HPA Strategic Research and Development Fund. (2012-2013): “Establishment of a lymphocyte adoptive transfer model”
  • Co-applicant, HPA Strategic Research and Development Fund. 1 year. £89k (2012-2013): “Characterization of antibody response in models of infectious diseases with human health impact”
  • Co-applicant, EU Framework 7. EUPRIM-Net II (2011-2015)
  • Co-applicant, HPA Strategic Research and Development Fund. (2010-2012)  “MHC Genetic characterization”
  • Co-applicant, EU Framework 6. EUPRIM-Net (2006-2009)
  • Careers
  • Terms and conditions
  • Accessibility
  • Privacy notice
  • Cookies
  • Sitemap